



MEDICAL TIPS

K-MET TABLETS

Issue I, No.2, 2024

Effect of Metformin Monotherapy and Combination Therapy with Glimepiride on Lipid Profile in Drug Naive Type-2 Diabetes Patients: A Prospective Observational Study

Pareek A, et al. *J. Pharm. Care.* 2023; 11(1): 2-5

- Altered lipid metabolism and abnormalities in serum lipid profile which results in “Atherogenic Dyslipidemia worsens the prognosis of diabetic patients.
- A prospective study of 120 prescriptions of drug naïve type-2 diabetic (T2DM) patients were analysed.
- Metformin monotherapy was found to significantly improve dyslipidemia [low density lipoprotein cholesterol (LDL-C) reduction from 92.3mg/dl to 83.2mg/dl and triglyceride reduction from 145.5mg/dl to 132 mg/dl) and reduced average blood glucose levels (from 193.4mg/dl to 135.2mg/dl).
- The lipid-modifying effect may be attributable to insulin sensitization, reduction of irreversibly glycated LDL-C and weight loss.

Metformin appreciably improved dyslipidemia in drug naive type-2 diabetes patients.

